Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avant, Celldex to merge

AVAN and Celldex (Phillipsburg, N.J.) will merge in a stock deal that values the combined company at $115 million based on AVAN's

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE